glp-1 gip and glucagon The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide Receptor GIP and GLP‐1, the two
Description
your doctor chooses based on your response Total ramp-up: ~20 weeks to reach maximum dose (if needed) Same protocol for both Mounjaro (diabetes) and Zepbound (weight loss) GLP-1 Dosage Chart: Tirzepatide Titration Schedule Tirzepatide is a dual GLP-1/GIP agonist, the active compound in both Mounjaro and Zepbound
Hypersensitivity reactions to tirzepatide, including anaphylaxis, have been reported in the FDA prescribing information
Exercise, particularly when combining aerobic and resistance modalities, exerts well-established benefits on muscle mass, strength, and function ( Preservation of lean mass during weight reduction is crucial, as skeletal muscle is a primary determinant of basal metabolic rate and glucose disposal
Patients who feel involved in their treatment plans are more likely to follow recommendations
A PRAGMATIC PATH TO A GREENER FUTURE The GLP-1 era is unfolding at a rapid pace, reshaping treatment landscapes for obesity and metabolic diseases
